Success Metrics

Clinical Success Rate
75.0%

Based on 3 completed trials

Completion Rate
75%(3/4)
Active Trials
0(0%)
Results Posted
33%(1 trials)
Terminated
1(20%)

Phase Distribution

Ph early_phase_1
1
20%
Ph phase_2
2
40%
Ph phase_1
1
20%

Phase Distribution

2

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Early Phase 1First-in-human
1(25.0%)
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
2(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(3)
Terminated(1)
Other(1)

Detailed Status

Completed3
Terminated1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
75.0%
Most Advanced
Phase 2

Trials by Phase

Early Phase 11 (25.0%)
Phase 11 (25.0%)
Phase 22 (50.0%)

Trials by Status

completed360%
terminated120%
unknown120%

Recent Activity

0 active trials
Showing 5 of 5
completedphase_2

Thrombosomes® in Acute Thoracic Aortic Dissections

NCT05771831
unknown

Thrombosomes for Expanded Access Use

NCT04619108
terminatedphase_2

Thrombosomes® in Bleeding Thrombocytopenic Patients Study

NCT04631211
completedphase_1

Thrombosomes® in Bleeding Thrombocytopenic Patients

NCT03394755
completedearly_phase_1

Evaluation of the Safety and Immunogenicity of Autologous Thrombosomes® in Healthy Human Subjects; A Microdose Escalation Study (Cohorts 1 - 4) and Repeat Microdose Immunogenicity Study (Cohort 5)

NCT02223117

Clinical Trials (5)

Showing 5 of 5 trials
NCT05771831Phase 2

Thrombosomes® in Acute Thoracic Aortic Dissections

Completed
NCT04619108

Thrombosomes for Expanded Access Use

Unknown
NCT04631211Phase 2

Thrombosomes® in Bleeding Thrombocytopenic Patients Study

Terminated
NCT03394755Phase 1

Thrombosomes® in Bleeding Thrombocytopenic Patients

Completed
NCT02223117Early Phase 1

Evaluation of the Safety and Immunogenicity of Autologous Thrombosomes® in Healthy Human Subjects; A Microdose Escalation Study (Cohorts 1 - 4) and Repeat Microdose Immunogenicity Study (Cohort 5)

Completed

All 5 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
5